Human Parainfluenza Virus 3 Infections - Pipeline Review, H1 2018

March 2018 | 32 pages | ID: H62157F2740EN
Global Markets Direct

Abstracts

Human Parainfluenza Virus 3 Infections - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H1 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.

Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Parainfluenza Virus 3 Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Human Parainfluenza Virus 3 Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Human Parainfluenza Virus 3 Infections - Overview
Human Parainfluenza Virus 3 Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Human Parainfluenza Virus 3 Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Parainfluenza Virus 3 Infections - Companies Involved in Therapeutics Development
3-V Biosciences Inc
Amarillo Biosciences Inc
Moderna Therapeutics Inc
Human Parainfluenza Virus 3 Infections - Drug Profiles
interferon alpha - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-1653 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Paradase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hemagglutinin and Neuraminidase for Human Parainfluenza Virus 1 and 3 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Parainfluenza Virus 3 Infections - Dormant Projects
Human Parainfluenza Virus 3 Infections - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Human Parainfluenza Virus 3 Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Human Parainfluenza Virus 3 Infections - Pipeline by 3-V Biosciences Inc, H1 2018
Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc, H1 2018
Human Parainfluenza Virus 3 Infections - Pipeline by Moderna Therapeutics Inc, H1 2018
Human Parainfluenza Virus 3 Infections - Dormant Projects, H1 2018
Human Parainfluenza Virus 3 Infections - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Human Parainfluenza Virus 3 Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

3-V Biosciences Inc
Amarillo Biosciences Inc
Moderna Therapeutics Inc